February 9, 2012

Dear Friends and Supporters of Us TOO,

Two global research studies, called the elm•pc studies, are seeking men with metastatic castration-resistant prostate cancer to participate in the effort to evaluate a new investigational oral medication, TAK-700, given with prednisone.

The studies will help determine if TAK-700, given with prednisone, can lengthen the lives of men with metastatic castration-resistant prostate cancer compared to prednisone alone.

Men enrolled in either study will be assigned to one of two groups: those who will receive the investigational oral medication, TAK-700, with prednisone, and those who will be treated with prednisone alone. Prednisone is asteroid commonly used to treat advanced prostate cancer.

TAK-700, an investigational oral lyase inhibitor, is being studied for individuals with metastatic prostate cancer.

The elm•pc studies are being conducted by Millennium: The Takeda Oncology Company. To learn more about the elm•pc studies call 1-855-493-5672 or visit  www.elmpctrials.com.

Please feel free to forward this message along to other men you know who are dealing with painful prostate cancer, or to physicians who might be interested in sharing the information with their other patients. Thank you in advance for your consideration and participation.

Sincerely,

Thomas Kirk President & CEO Us TOO International Downers Grove, IL 60655 Office: 630-795-1002 Toll Free: 800-808-7866 tom@ustoo.org